Edwards Lifesciences Co. (NYSE:EW) Stock Holdings Boosted by Columbia Trust Co 01012016

Columbia Trust Co 01012016 raised its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 26.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 21,125 shares of the medical research company’s stock after buying an additional 4,380 shares during the period. Columbia Trust Co 01012016’s holdings in Edwards Lifesciences were worth $1,611,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in EW. Moneta Group Investment Advisors LLC boosted its holdings in Edwards Lifesciences by 104,971.3% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 15,399,249 shares of the medical research company’s stock worth $1,148,938,000 after buying an additional 15,384,593 shares in the last quarter. Norges Bank bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth $658,390,000. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST boosted its stake in shares of Edwards Lifesciences by 440.0% during the 3rd quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 3,510,000 shares of the medical research company’s stock worth $243,173,000 after acquiring an additional 2,860,000 shares in the last quarter. AustralianSuper Pty Ltd bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth $168,519,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its stake in shares of Edwards Lifesciences by 655.9% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,325,457 shares of the medical research company’s stock worth $173,502,000 after acquiring an additional 2,017,801 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, Director Michael A. Mussallem sold 29,350 shares of the business’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $72.98, for a total value of $2,141,963.00. Following the completion of the sale, the director now owns 4,486 shares of the company’s stock, valued at $327,388.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, Director Michael A. Mussallem sold 29,350 shares of the business’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $72.98, for a total value of $2,141,963.00. Following the completion of the sale, the director now directly owns 4,486 shares in the company, valued at $327,388.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Catherine M. Szyman sold 27,000 shares of the business’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the completion of the sale, the vice president now owns 34,814 shares of the company’s stock, valued at $2,980,774.68. The disclosure for this sale can be found here. In the last 90 days, insiders sold 196,859 shares of company stock valued at $16,445,296. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Up 0.3 %

Shares of Edwards Lifesciences stock traded up $0.26 during trading on Tuesday, hitting $93.42. 2,747,859 shares of the stock traded hands, compared to its average volume of 4,085,825. The stock has a market cap of $56.17 billion, a P/E ratio of 40.62, a PEG ratio of 4.65 and a beta of 1.05. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.40 and a current ratio of 3.38. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $95.27. The company has a fifty day moving average price of $85.09 and a two-hundred day moving average price of $75.72.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.64. The firm had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The company’s revenue was up 13.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.64 earnings per share. Equities research analysts predict that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on EW shares. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research report on Thursday, March 7th. Royal Bank of Canada raised their target price on shares of Edwards Lifesciences from $82.00 to $95.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. Wolfe Research lowered shares of Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $57.00 price objective for the company. in a research note on Tuesday, November 28th. Morgan Stanley raised their price objective on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a research note on Thursday, March 21st. Finally, OTR Global upgraded Edwards Lifesciences from a “mixed” rating to a “positive” rating in a report on Tuesday. One analyst has rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences has an average rating of “Hold” and a consensus target price of $88.50.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.